Patents Issued in May 12, 2020
-
Patent number: 10646465Abstract: Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and/or cell migration, and/or treating disease and disorders such as cancer and inflammatory diseases and disorders, are provided herein. The compounds are listed in Tables 2, 4 and 5, and/or are represented by Formulae I, IV, V and VI, as defined in the specification. Methods utilizing these compounds are also provided.Type: GrantFiled: December 15, 2016Date of Patent: May 12, 2020Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Abraham, Orly Eizenberg
-
Patent number: 10646466Abstract: A method for at least one of increasing the synthesis of melatonin and promoting the secretion of melatonin is provided, wherein the method comprises administering to a subject in need an effective amount of a compound of formula (I): A method for at least one of treating diseases related to neurometabolic disorder, preventing diseases related to neurometabolic disorder, regulating appetite, regulating mood, regulating vasoconstriction, regulating hemostatic function and regulating immune response is also provided, wherein the method comprises administering to a subject in need an effective amount of a compound of formula (I) as described above.Type: GrantFiled: November 6, 2018Date of Patent: May 12, 2020Assignee: TCI CO., LTD.Inventors: Yung-Hsiang Lin, Chin-Hsiu Yu, Yu-Hung Su, Shan-Yu Lin, Yu-Ming Chung
-
Prodrug of green tea epigallocatechin-3-gallate (pro-EGCG) for use in the treatment of endometriosis
Patent number: 10646467Abstract: Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin-3-gallate [(?)-EGCG]. Use of PRO-EGCG in the manufacture of a medicament for treating endometriosis and related indications. Pro-EGCG for use in the treatment of endometriosis and related indications.Type: GrantFiled: January 28, 2019Date of Patent: May 12, 2020Inventors: Tak-Hang Chan, Chi-Chiu Wang -
Patent number: 10646468Abstract: A composition which comprises substance represented by Formula (I), [Meanings of the symbols that are included in the formula are given in the specification as definitions] a pharmaceutically acceptable carrier, and a dissolution aid.is useful for improving solubility, oral absorbability and/or absorbability in blood of a poorly water-soluble or water insoluble tetracyclic compounds having an ALK inhibitory activity that are useful as a prophylactic and/or therapeutic agent for cancer, depression, and cognitive function disorder.Type: GrantFiled: May 11, 2016Date of Patent: May 12, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kentaro Furumoto, Koji Shiraki, Tomoaki Hirayama
-
Patent number: 10646469Abstract: The present invention concerns substituted indole derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: March 31, 2017Date of Patent: May 12, 2020Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
-
Patent number: 10646470Abstract: Methods and compositions for treating acute myeloid leukemia and diffuse large B cell lymphoma using combinations of venetoclax and indolinone derivatives are provided.Type: GrantFiled: August 27, 2018Date of Patent: May 12, 2020Assignee: Oncternal Therapeutics, Inc.Inventors: Brian Lannutti, Katayoun Jessen, James Bradley Breitmeyer
-
Patent number: 10646471Abstract: The disclosure provides bisindole suitable for inhibiting lipoxygenases or A?-formation, and treating associated diseases, such as Alzheimer's disease. The bisindoles are indolo[2,3-b]carbazole derivatives, and may be administered to a patient as part of a pharmaceutical formulation.Type: GrantFiled: December 15, 2016Date of Patent: May 12, 2020Assignee: SRI InternationalInventor: Ling Jong
-
Patent number: 10646472Abstract: Embodiments of a composition comprising a photosensitive compound and a polymer nanoparticle are disclosed herein. The composition may further comprise a targeting moiety. In some embodiments, the photosensitive compound is a phthalocyanine or phthalocyanine derivative, such as a naphthalocyanine. Upon irradiation with near infrared light, the composition may be used as a fluorescent imaging agent and/or as a phototherapeutic agent, such as for photodynamic and/or photothermal therapies. In certain embodiments, the composition is used to treat certain cancers.Type: GrantFiled: October 17, 2017Date of Patent: May 12, 2020Assignee: Oregon State UniversityInventors: Olena Taratula, Oleh Taratula, Adam Alani
-
Patent number: 10646473Abstract: The subject matter disclosed herein is directed to stable, highly-effective topical formulations comprising permethrin, fipronil and a solvent system that is sufficient to solubilize these two active ingredients and limit degradation of fipronil to its sulfone, and their uses in topical applications on animals and the environment. Useful formulations comprise from about 30% to about 55% (w/w) permethrin and about 2 to 15% (w/w) fipronil and a solvent system that comprises N-methyl pyrrolidone and a glycol, glycol ether, glycol ester, fatty acid ester or neutral oil, wherein the N-methyl pyrrolidone and glycol, glycol ether, glycol ester, fatty acid ester or neutral oil are present in a weight: weight ratio of from about 1:2.0 to about 1:3.5, glycol, glycol ether, glycol ester, fatty acid ester or neutral oil to n-methyl pyrrolidone. These two actives when combined in the described amounts have been found to have unexpected enhanced repellent activity against stable fly.Type: GrantFiled: March 28, 2018Date of Patent: May 12, 2020Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.Inventors: Mark David Soll, James Pate, Lisa A. Baker
-
Patent number: 10646474Abstract: Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM.Type: GrantFiled: August 23, 2019Date of Patent: May 12, 2020Assignee: Corcept Therapeutics, Inc.Inventors: Hazel Hunt, Thaddeus S. Block
-
Patent number: 10646475Abstract: The present invention relates to a method for the treatment of cancer or an autoimmune disorder, comprising the administration of a serine hydroxymethyltransferase (SHMT) inhibitor, and in particular the administration of pyrazolopyran compounds of Formula (VI) as presently described, wherein the compounds are capable of inhibiting a mammalian SHMT, such as human SHMT1 and/or SHMT2. The treatment method further comprises the optional administration of an additional agent as a rescue therapy to reduce toxicity, wherein said agent may be chosen from formate, a formate salt, folinic acid, formate ester, or leucovorin.Type: GrantFiled: March 10, 2016Date of Patent: May 12, 2020Assignee: The Trustees of Princeton UniversityInventors: Joshua D. Rabinowitz, Hahn Kim, Gregory S. Ducker, Jonathan M. Ghergurovich
-
Patent number: 10646476Abstract: The present invention concerns compositions for the increase in the humoral secretion comprising imidazole peptides or extracts containing them, as well as the use of said compositions for the prevention and/or treatment of secretarial dysfunctions of the body mucosa.Type: GrantFiled: July 26, 2016Date of Patent: May 12, 2020Assignee: Metis Healthcare S.r.l.Inventors: Cristiano Umberto Rumio, Francesco Palladini
-
Patent number: 10646477Abstract: The present invention concerns the synthesis and use of formulations of 5-substituted 2, 4-thiazolidinediones, pseudothiohydantoins, and propseudothiohydantoins and 2, 4-thiazolidinediones metforminate salts for topical and systemic treatments of infections caused by herpes simplex viruses and varicella zoster viruses.Type: GrantFiled: May 25, 2018Date of Patent: May 12, 2020Assignee: Jiva Pharma, Inc.Inventor: Om P Goel
-
Patent number: 10646478Abstract: Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.Type: GrantFiled: July 6, 2018Date of Patent: May 12, 2020Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTEInventors: Leonard Zon, Richard M. White
-
Patent number: 10646479Abstract: Disclosed herein is the use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetra-hydropyridine as a treatment for cancer.Type: GrantFiled: September 27, 2019Date of Patent: May 12, 2020Assignee: Florida A&M UniversityInventors: Elizabeth Henderson, Tiffany Wilson Ardley, Kinfe Ken Redda, Madhavi Gangapuram
-
Patent number: 10646480Abstract: Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.Type: GrantFiled: September 16, 2019Date of Patent: May 12, 2020Assignee: ACADIA Pharmaceuticals Inc.Inventors: Ravi Tejwani, Stephen Edward Abele, Emanuel Joseph Vizzotti
-
Patent number: 10646481Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.Type: GrantFiled: August 31, 2016Date of Patent: May 12, 2020Assignee: Vertex Pharmaceuticals IncorporatedInventors: William Rowe, Patricia Hurter, Christopher Young, Kirk Dinehart, Marinus Jacobus Verwijs, Kirk Overhoff, Peter D. J. Grootenhuis, Martyn Botfield, Alfredo Grossi
-
Patent number: 10646482Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.Type: GrantFiled: August 22, 2018Date of Patent: May 12, 2020Assignee: FibroGen, Inc.Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
-
Patent number: 10646483Abstract: The present invention relates to the crystal form of imidazolone type compounds, and a preparation method, pharmaceutical composition and use thereof, and falls within the field of pharmaceutical compound crystals. The crystal form provided by the present invention has a good stability, comprising good stability under the three extreme conditions of high temperature, high humidity and strong illumination, and can also maintain a good stability during the tablet compressing process. The crystal form provided by the present invention has good absorption and metabolism properties in vivo, comprising the drug concentration of blood, the drug concentration-time curve AUC, the half-life period, etc. In addition, the dissolving rate of the crystal form of the present invention is improved, wherein same is beneficial for the applications thereof in preparations.Type: GrantFiled: January 26, 2016Date of Patent: May 12, 2020Assignee: Foreland Pharma Co., Ltd.Inventors: Qi Ji, Zhenjian Du, Xingmin Zhang, Lei Wang, Congmin Gao, Longlong Gong
-
Patent number: 10646484Abstract: The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.Type: GrantFiled: June 22, 2018Date of Patent: May 12, 2020Assignee: INDIVIOR UK LIMITEDInventors: Celine M. Laffont, Malcolm A. Young, Norma L. Fox, Barbara R. Haight, Susan M. Learned
-
Patent number: 10646485Abstract: The present disclosure relates to cured pharmaceutical compositions designed to reduce the potential for improper administration of drugs that are subject to abuse, the process of curing such composition in order to improve the dissolution stability, method of using the same for treatment of pain.Type: GrantFiled: December 13, 2018Date of Patent: May 12, 2020Assignee: Collegium Pharmaceutical, Inc.Inventors: Said Saim, Alison B. Fleming, Ravi K. Varanasi
-
Patent number: 10646486Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A?, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: September 14, 2017Date of Patent: May 12, 2020Assignee: Gilead Sciences, Inc.Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Jeromy J. Cottell, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Philip Anthony Morganelli, Hyung-Jung Pyun
-
Patent number: 10646487Abstract: The present invention provides an agent containing an orotic acid derivative that has high solubility in solvent and has superior physiological activity. The agent of the present invention is a melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promoter or wrinkle ameliorant containing as an active ingredient thereof an orotic acid derivative represented by the following general formula (1) or a salt thereof. In formula (1), R preferably represents a side chain of glutamic acid, glycine, histidine or aspartic acid. [In formula (1), R represents a side chain of a naturally-occurring amino acid and R may form, together with a nitrogen atom adjacent thereto through a single carbon atom, a hetero ring].Type: GrantFiled: June 8, 2017Date of Patent: May 12, 2020Assignee: SHOWA DENKO K.K.Inventors: Daisuke Yagyu, Yuko Nakagami, Ryota Niibayashi, Eiko Kato
-
Patent number: 10646488Abstract: Conjugates of a cereblon-binding compound and compounds having modulatory activity against G12C mutant KRAS, HRAS or NRAS G12C proteins are provided. Methods associated with preparation and use of such conjugates, pharmaceutical compositions comprising such conjugates and methods to modulate the activity of G12C mutant KRAS, HRAS or NRAS G12C proteins for treatment of disorders, such as cancer, are also provided.Type: GrantFiled: July 13, 2017Date of Patent: May 12, 2020Assignee: ARAXES PHARMA LLCInventors: Yi Liu, Liansheng Li, Pingda Ren
-
Patent number: 10646489Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions comprise a combination of a PDE 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite.Type: GrantFiled: February 7, 2018Date of Patent: May 12, 2020Assignee: NuSirt Sciences, Inc.Inventors: Michael Zemel, Antje Bruckbauer, Brooke Baggett
-
Patent number: 10646490Abstract: The present invention provides for the design and synthesis of halogenated thieno- and pyrrolopyrimidine compounds and prodrugs thereof that exhibit cancer proliferation inhibitory activity and the use thereof for cancer treatment.Type: GrantFiled: February 1, 2019Date of Patent: May 12, 2020Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTYInventor: Katherine L. Radtke
-
Patent number: 10646491Abstract: An object of the present invention is to provide pharmaceutical agents that reduce risk for decrease in bone mineral density due to their effect of reducing estrogen levels and exert excellent therapeutic effects on endometriosis. The present invention relates to pharmaceutical compositions for treating endometriosis comprising 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmaceutically acceptable salt thereof, which are administered orally once a day at a daily dose of between 50 mg and 75 mg calculated as a free form.Type: GrantFiled: August 7, 2017Date of Patent: May 12, 2020Assignee: KISSEI PHARMACEUTICAL CO., LTD.Inventors: Takuro Dan, Hideomi Takahashi, Yu Kuramochi
-
Patent number: 10646492Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.Type: GrantFiled: June 19, 2019Date of Patent: May 12, 2020Assignees: Incyte Corporation, Incyte Holdings CorporationInventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks
-
Patent number: 10646493Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.Type: GrantFiled: July 17, 2019Date of Patent: May 12, 2020Assignee: Signal Pharmaceuticals, LLCInventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
-
Patent number: 10646494Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A?, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.Type: GrantFiled: August 14, 2017Date of Patent: May 12, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Wensheng Yu, Ling Tong, Joseph A. Kozlowski, Craig A. Coburn, De-Yi Yang, Deyou Sha, Jae-Hun Kim, Michael Dwyer, Kartik M Keertikar, Bin Hu, Bin Zhong, Jinglai Hao, Dahai Wang
-
Patent number: 10646495Abstract: Testosterone ester triglyceride formulations, optionally further including adducts. Methods of in-situ control of the manufacture or formation of such adducts are also described.Type: GrantFiled: August 30, 2018Date of Patent: May 12, 2020Assignee: Antares Pharma, Inc.Inventor: Shaowei Ong
-
Patent number: 10646496Abstract: The present invention provides joint use of stain and adrenocortical hormone for preparing a pharmaceutical product for the treatment of chronic subdural hematoma. The pharmaceutical product according to the present invention is capable of accelerating hematoma absorption and improving a therapeutic effect of single oral administration of a statin-based pharmaceutical product, and the dose of the adrenocortical hormone-based pharmaceutical product used is 1/10 of the dose used in a large-dose hormonal therapy.Type: GrantFiled: December 29, 2016Date of Patent: May 12, 2020Inventors: Jianning Zhang, Rongcai Jiang, Dong Wang
-
Patent number: 10646497Abstract: The present invention relates to certain cortexolone derivatives of formula (I) and the use of the same as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. The present invention also relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of the pharmaceutical compositions as antitumor medicinal products.Type: GrantFiled: November 23, 2018Date of Patent: May 12, 2020Assignee: COSMO TECHNOLOGIES LIMITEDInventor: Mara Gerloni
-
Patent number: 10646498Abstract: A composition for preventing or treating muscle diseases or improving muscular function, containing fucosterol, Sargassum fulvellum, a Sargassum fulvellum dried powder, a Sargassum fulvellum extract, Sargassum fusiforme, a Sargassum fusiforme dried powder or a Sargassum fusiforme extract is disclosed. Fucosterol, Sargassum fulvellum, a Sargassum fulvellum dried powder, a Sargassum fulvellum extract, Sargassum fusiforme, a Sargassum fusiforme dried powder or a Sargassum fusiforme extract increases the protein expression of p-mTOR, which is a main gene involved in muscle protein synthesis, inhibits the mRNA expression of MuRF-1 and atrogin-1 involved in muscle protein degradation, and increases the mRNA expression of MyoD and myogenin involved in muscle differentiation, thereby having an effect of remarkably increasing muscular function. In addition, the composition can be safely used without side effects, thereby being usable in medicine, food, cosmetic products, livestock feed, a feed additive and the like.Type: GrantFiled: May 26, 2016Date of Patent: May 12, 2020Assignee: AAT COSTECH CO., LTD.Inventors: Jae Kwan Hwang, Chang Hee Kim, Mi-Bo Kim
-
Patent number: 10646499Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.Type: GrantFiled: July 9, 2018Date of Patent: May 12, 2020Assignee: Intercept Pharmaceuticals, Inc.Inventors: Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
-
Patent number: 10646500Abstract: The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.Type: GrantFiled: October 3, 2014Date of Patent: May 12, 2020Assignee: GLENMARK SPECIALTY S.A.Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram Mansingh Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
-
Patent number: 10646501Abstract: Provided are compositions and methods for reducing the reproductive capacity of mammals. The compositions and methods involve the use and administration of (a) a diterpenoid epoxide comprising a triptolide skeleton and which causes ovarian follicle depletion in female mammals and (b) an organic diepoxide which causes ovarian follicle depletion in female mammals.Type: GrantFiled: February 22, 2018Date of Patent: May 12, 2020Assignee: SENESTECH, INC.Inventors: Lorretta P. Mayer, Cheryl A. Dyer
-
Patent number: 10646502Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.Type: GrantFiled: September 13, 2017Date of Patent: May 12, 2020Assignee: Lawrence Livermore National SecurityInventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
-
Patent number: 10646503Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.Type: GrantFiled: September 25, 2019Date of Patent: May 12, 2020Assignee: Celgene CorporationInventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
-
Patent number: 10646504Abstract: Disclosed herein are pharmaceutical compositions that comprise “blends” of lipid nanoparticles and related methods of using such blended compositions to deliver polynucleotides to one or more target cells, tissues or organs. The blended compositions are generally characterized as being able to efficiently deliver polynucleotides to target cells and by their ability to enhance the expression of such polynucleotides and the production of functional proteins by target cells.Type: GrantFiled: October 10, 2018Date of Patent: May 12, 2020Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Lianne Smith, Michael Heartlein, Braydon Charles Guild
-
Patent number: 10646505Abstract: This disclosure is directed to structured compositions, including DNA-functionalized scaffolds, for drug capture, and methods and devices for sequestering chemotherapeutics from physiological fluids using the functionalized scaffolds.Type: GrantFiled: September 6, 2017Date of Patent: May 12, 2020Assignee: California Institute of TechnologyInventors: Michael D. Schulz, Carl M. Blumenfeld, Robert H. Grubbs, Julia R. Greer, Daryl Wei Liang Yee
-
Patent number: 10646506Abstract: The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol and existing in gel form in aqueous solution at a concentration ?1% at 25° C. and neutral pH and having a melting temperature (gel to sol) of 30 to 44° C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan.Type: GrantFiled: November 14, 2016Date of Patent: May 12, 2020Assignee: Biotec Pharmacon AsaInventors: Rolf Engstad, Thor Nøkland
-
Patent number: 10646507Abstract: Compositions and methods for improving transperitoneal oxygen uptake during peritoneal ventilation for extrapulmonary oxygenation of an organism or individual organs in preferably life-threatening case of need, such as pulmonary failure or circulatory shock, are disclosed. Such deficiencies can be addressed by transperitoneal administration of oxygen via a gas introduced into the abdominal cavity. A liquid, preferably aqueous, composition including an oxygen carrier such as hemoglobin is used, which, surprisingly, is capable of increasing the effectiveness of the diffusion of the oxygen administered by a one-time or repeated filling or continuous flushing of the abdominal cavity. An oxygen carrier, such as hemoglobin or derivatives thereof, is used for the manufacture of a composition for improvement of the diffusion of oxygen (gas) introduced into mucus layers of the peritoneum, preferably to enhance the diffusion of oxygen in transperitoneal ventilation.Type: GrantFiled: August 27, 2014Date of Patent: May 12, 2020Assignee: Sangui BioTech International, Inc.Inventors: Harald Poetzschke, Hubertus Schmelz
-
Patent number: 10646508Abstract: A method of making a composition or a dietary supplement is provided, the method comprising combining a quantity of a Nitrate with a quantity of an Amino Acid Compound, wherein the combining of the Nitrate with the Amino Acid Compound reduces a side effect or toxicity of the Nitrate. Also provided is a method of safely administering to a subject a Nitrate with a reduced side effect or toxicity, the method comprising: combining a quantity of the Nitrate with a quantity of an Amino Acid Compound in a composition or a dietary supplement, wherein the combining of the Nitrate with the Amino Acid Compound reduces the side effect or toxicity of the Nitrate; and safely administering to the subject the composition or dietary supplement comprising the Nitrate with the reduced side effect or toxicity.Type: GrantFiled: February 9, 2015Date of Patent: May 12, 2020Assignee: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Patent number: 10646510Abstract: In one embodiment, a confectionary comprises at least one sweetener, at least one stabilizer, at least one emulsifier, water, a first active ingredient, and an enrobing layer. The water may comprise 2 to 20 wt. % of the confectionary. The confectionary may have a water activity of from 0.45 to 0.65. The confectionary may be aerated such that the density of the confectionary is 0.7 to 1.25 grams per cubic centimeter. The confectionary may have a pH of 5.0 to 8.0.Type: GrantFiled: February 1, 2017Date of Patent: May 12, 2020Assignee: Eclaire Farm, LLCInventors: Martin Rifkin, Charles Bedell
-
Patent number: 10646511Abstract: This invention relates to medicine, more specifically, to cardiac surgery, and may be used for protecting the heart from ischemia when administering cardioplegia in normothermia or hypothermia. The general-purpose cardioplegic solution contains pharmaceutically acceptable potassium ions; magnesium ions; a base and an acid providing a pH buffer in a range of 7.1-8.9; a diuretic providing osmolality in a range of 275-460 mOsmol/kg. Said solution is used for cardiac protection in cardiopulmonary bypass, as well as for achieving asystole and maintaining the achieved asystole. The procedure for administering the general-purpose cardioplegic solution involves maintaining the achieved asystole by decreasing the flow rate of starting components of said solution relative to the flow rate of autoblood thus decreasing the solution to autoblood ratio.Type: GrantFiled: June 5, 2015Date of Patent: May 12, 2020Assignee: LIMITED LIABILITY COMPANY “CARDIOSYSTEMPHARMA” (LLC “CSP”)Inventor: Valentin Evgenevich Volgushev
-
Patent number: 10646512Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: —administering to the subject an effect amount of a first cleansing solution; and then after a time interval—administering to the subject an effective amount of a second cleansing solution, wherein the two cleansing solutions are as described in the specification.Type: GrantFiled: January 16, 2017Date of Patent: May 12, 2020Assignee: NORGINE BVInventors: Marc Halphen, Hans-Jurgen Gruss, Ian Cox, Alasdair Cockett, Peter Stein, Alex Ungar
-
Patent number: 10646514Abstract: Methods for processing and or removing organic residuals and or impurities from a solgel-derived bioactive glass-ceramic and compositions comprising solgel-derived bioactive glass-ceramics processed using these methods, are described.Type: GrantFiled: April 4, 2017Date of Patent: May 12, 2020Assignee: NOVABONE PRODUCTS, LLCInventors: Chloë Goldbach, Gregory J. Pomrink, Roy Layne Howell, Meryem Demir
-
Patent number: 10646515Abstract: The present invention relates to composition comprising an isolated CD8+ Treg cell population, wherein the Treg cells have signatures for i) identifying that the T-cells are CD8+ regulatory Tcells, ii) identifying that the Treg cells are tissue type tropic, i.e they can migrate to the diseased tissue, iii) optionally identifying that the Treg cells are tropic with respect to the diseased tissue, i.e. they are homing cells, iv) identifying that the Treg cells are emigrant cells, i.e. they originate from the target tissue, and v) optionally identifying that the Treg cells are capable of being retained in the target tissue and optionally one or more X-signatures and/or one or more Y-signatures.Type: GrantFiled: April 16, 2015Date of Patent: May 12, 2020Assignee: GENOVIE ABInventors: Reagan Micheal Jarvis, Magnus Thörn
-
Patent number: 10646516Abstract: Provided herein are pharmaceutical compositions comprising tumoricidal and/or antimicrobial components isolated from the supernatant of NK-92 cell medium and methods of using the compositions for killing cancer cells.Type: GrantFiled: December 6, 2018Date of Patent: May 12, 2020Assignee: NantKwest, Inc.Inventors: Hans G. Klingemann, Barry J. Simon